Prospective therapeutic applications of p53 inhibitors
- 2 April 2005
- journal article
- review article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 331 (3), 726-736
- https://doi.org/10.1016/j.bbrc.2005.03.153
Abstract
P53, in addition to being a key cancer preventive factor, is also a determinant of cancer treatment side effects causing excessive apoptotic death in several normal tissues during cancer therapy. p53 inhibitory strategy has been suggested to protect normal tissues from chemo- and radiotherapy, and to treat other pathologies associated with stress-mediated activation of p53. This strategy was validated by isolation and testing of small molecule p53 inhibitor pifithrin-α that demonstrated broad tissue protecting capacity. However, in some normal tissues and tumors p53 plays protective role by inducing growth arrest and preventing cells from premature entrance into mitosis and death from mitotic catastrophe. Inhibition of this function of p53 can sensitize tumor cells to chemo- and radiotherapy, thus opening new potential application of p53 inhibitors and justifying the need in pharmacological agents targeting specifically either pro-apoptotic or growth arrest functions of p53.Keywords
This publication has 96 references indexed in Scilit:
- Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in miceOncogene, 2004
- Inhibition of p53, p21 and Bax by pifithrin-α does not affect UV induced apoptotic response in CS-B cellsDNA Repair, 2003
- p53 Inhibitor Pifithrin α Can Suppress Heat Shock and Glucocorticoid Signaling PathwaysPublished by Elsevier BV ,2003
- The C-terminal Fragment of Presenilin 2 Triggers p53-mediated Staurosporine-induced Apoptosis, a Function Independent of the Presenilinase-derived N-terminal CounterpartPublished by Elsevier BV ,2003
- The role of p53 in determining sensitivity to radiotherapyNature Reviews Cancer, 2003
- Pifithrin-α, an inhibitor of p53, enhances the genetic instability induced by etoposide (VP16) in human lymphoblastoid cells treated in vitroMutation Research, 2002
- Disruption of p53 in human cancer cells alters the responses to therapeutic agentsJCI Insight, 1999
- Could p53 be a target for therapeutic suppression?Seminars in Cancer Biology, 1998
- Transgenic mice with p53-responsive lacZ: p53activity varies dramatically during normal development and determines radiation and drug sensitivity invivoThe EMBO Journal, 1997
- p53 is required for radiation-induced apoptosis in mouse thymocytesNature, 1993